



# The 1st International Forum of Fabry Disease 第1回国際ファブリ病フォーラム

第3報

日時

2026年 **Oct. 2, (FRI) 9:00 - 18:30** | **Oct. 3, (SAT) 9:00 - 14:20**

会場

東京慈恵会医科大学 1号館 3階講堂  
Tokyo Jikei University School : Main Auditorium

President: Yoshikatsu Eto (Southern Tohoku Institute for Neuroscience/ The Jikei Univ.School of Medicine)

Vice President: Masahisa Kobayashi (The Jikei Univ.School of Medicine)

共催：NPO 法人日本ライソゾーム病研究センター、国際ライソゾーム病フォーラム、  
厚生労働省難治性疾患行政事業ライソゾーム病小林班、財) 脳神経疾患研究所

## Program (Tentative)

### Day 1 / Oct. 2 (FRI)

9:00-9:20

Chair: R. Desnick (Cahn School of Medicine at Mount Sinai, USA)

#### Opening and New proposal of Fabry disease after NBS

Y. Eto (Southern Tohoku Institute for Neuroscience / The Jikei Univ. School of Medicine, Japan)

9:20-10:20

#### Unique Case Presentations of Fabry disease

Chair: A. Narita (Iseikai International General Hospital, Japan)

M. Kobayashi (The Jikei Univ. School of Medicine, Japan)

#### 1) Sudden ventricular tachycardia and fibrillation in male late-onset Fabry disease

T. Okuyama (The Jikei Univ. School of Medicine, Japan)

#### 2) Reduced recurrence of cerebrovascular events following switching to agalsidase beta in Fabry disease: two case reports

Y. Fujita (The Jikei Univ. School of Medicine, Japan)

#### 3) Clinical Decision Making for Diagnosis and Treatment Initiation in Late Onset Mild Fabry Disease

K. Eto (Tokyo Women's Medical Univ. Adachi Medical Center, Japan)

#### 4) SGLT2 Inhibitors in Fabry Disease: Evidence of Renoprotection from Case-Based and Clinical Analyses

H. Okamoto (Kobe Univ. Graduate School of Medicine, Japan)

10:30-11:10 (Co-sponsored by Sanofi)

Chair: Y. Eto (Southern Tohoku Institute for Neuroscience / The Jikei Univ. School of Medicine, Japan)

#### Fabry Disease: Major Advances in Delineation, Diagnosis and Treatment

R. Desnick (Cahn School of Medicine at Mount Sinai, USA)

11:10-12:10 (Co-sponsored by Sumitomo Pharma)

#### Key Points on Fabry Disease and LysoGb3

Chair: M. Kosuga (National Center for Child Health and Development, Japan)

K. Tsuboi (Nagoya Central Hospital, Japan)

#### 1) Biomarkers in Fabry disease: Diagnosis and treatment monitoring

T. Tsukimura (Meiji Pharmaceutical Univ., Japan)

#### 2) A biochemical and pharmacological comparison of three agalsidases approved and used in Japan

H. Sakuraba (Meiji Pharmaceutical Univ., Japan)

12:20-13:00 Luncheon Seminar (Co-sponsored by JCR)

Chair: T. Okuyama (Juntendo Univ., Japan)

#### Fabry disease: Real World evidence (RWE) of Treatment

R. Giugliani (Federal Univ. of Rio Grande do Sul, Brazil)

13:10-13:40

#### New Therapy

Chair: DM. Niu (National Yang Ming Chiao Tung Univ., Taiwan)

#### Splicing Modulation Therapy for Taiwanese Cardiac Fabry Disease (GLA c.639+919G>A)

T. Awaya (Osaka Metropolitan Univ. Graduate School of Medicine, Japan)

13:40-14:20

Chair: Y. Yuzawa (Vice Chairperson, Fujita Gakuen Educational Foundation, Japan)

#### Second Generation ERTs for Fabry Disease

D. Warnock (The Univ. of Alabama at Birmingham, USA)

14:20-15:30

#### Organ Specific Outcomes - Kidney, Heart and Brain

##### 1. Renal problems

Chair: D. Warnock (The Univ. of Alabama at Birmingham, USA)

O. Migita (St. Marianna Univ. School of Medicine, Japan)

#### 1) The Evolving Landscape of Fabry Nephropathy

N. Nakagawa (Asahikawa Medical Univ., Japan)

#### 2) TBA

C. Tøndel (Univ. of Bergen, Norway)

15:40-17:10

#### Organ Specific Outcomes - Kidney, Heart and Brain

##### 2. Cardiovascular/CNS events

Chair: H. Yamakawa (Keio Univ. School of Medicine, Japan)

K. Nakamura (Shinshu Univ. School of Medicine, Japan)

#### 1) Multimodality imaging for the evaluation of cardiac involvement in Fabry disease

K. Hongo (The Jikei Univ. School of Medicine, Japan)

#### 2) TBA

Y. Nakazato (Saitama Medical Univ., Japan)

#### 3) TBA

Alessandro Burlina (Univ. Hospital of Padova, Italy)

17:10-17:50

Chair: T. Iwamoto (Southern Tohoku Institute for Neuroscience / The Jikei Univ. School of Medicine, Japan)

R. Giugliani (Federal Univ. of Rio Grande do Sul, Brazil)

#### LysoGb3 as a Biomarker in Fabry disease

A. Nowak (Univ. of Zurich, Switzerland)

17:50-18:30

Chair: H. Ida (The Jikei Univ. School of Medicine, Japan)

#### Antidrug antibodies in Fabry disease: Effects, measurement challenges and future directions

M. Lenders (Interdisciplinary Fabry Center (IFAZ), Univ. Hospital Muenster, Germany)

19:00-21:00

Banquet @ The Prince Park Tower Tokyo

### Day 2 / Oct. 3 (SAT)

9:00-10:20

Chair: H. Kobayashi (The Jikei Univ. School of Medicine, Japan)

T. Ohashi (The Jikei Univ. School of Medicine, Japan)

#### 1) AAV Gene Therapy in Fabry disease

R.J. Hopkin (Cincinnati Children's Hospital Medical Center, USA)

#### 2) Lentivirus-Mediated Gene Therapy for Fabry Disease: Long-Term Results and New Initiatives

J.A. Medin (Medical College of Wisconsin, USA)

10:20-12:50

Chair: K. Nakamura (Kumamoto Univ. Graduate School of Medical Sciences, Japan)

YH Chien (National Taiwan Univ., Taiwan)

#### Newborn screening of Fabry disease: Workshop

K. Nakamura / T. Sawada (Kumamoto Univ. Graduate School of Medical Sciences, Japan)

YH Chien (National Taiwan Univ., Taiwan)

DM. Niu (National Yang Ming Chiao Tung University, Taiwan)

B. K. Burton (Northwestern Univ., USA)

A. Burlina (Univ. Hospital of Padova, Italy)

13:00-14:10 Luncheon seminar (Co-sponsored by Amicus Therapeutics)

#### Pharmacological Chaperones: New Frontier

Chair: D. Hughes (Univ. College London, UK)

N. Sakai (ISEIKAI International General Hospital, Japan)

#### Japanese Experience

M. Kobayashi (The Jikei Univ. School of Medicine, Japan)

#### New Frontier in Fabry Management

D. Hughes (Univ. College London, UK)

14:10-14:20

Closing Remark M. Kobayashi (The Jikei Univ. School of Medicine, Japan)

Secretariat | Intergroup Co., Ltd. (Contact: Izumi (Mr.))

6th Floor, Sumitomo Life Akasaka Building, 3-3-3 Akasaka, Minato-ku, Tokyo 107-0052 Email: forum-secret@ig-online.jp

事務局 | インターグループ内 (担当: 和泉) 〒107-0052 東京都港区赤坂三丁目 3-3 住友生命赤坂ビル 6階 forum-secret@ig-online.jp